Aurisco's Landmark FDA Approval Cracks Open High-Cost Drug Market

SHANGHAI – August 12, 2026 – A critical barrier in the world of advanced pharmaceuticals has been quietly but decisively broken. Aurisco Pharmaceutical, a Shanghai-listed company, announced that its manufacturing site in Yangzhou, China, has become the first facility in the world to pass a U.S. Food and Drug Administration (USFDA) inspection for the manufacturing of a generic oligonucleotide active pharmaceutical ingredient (API). The approval, a milestone for both the company and the global pharmaceutical landscape, signals the dawn of a new era where some of the most complex and expensive medicines could become significantly more affordable.

The five-day pre-approval inspection, conducted in June, centered on the API for Inclisiran Sodium, a cutting-edge cholesterol-lowering therapy. This successful audit not only validates Aurisco's manufacturing prowess but also establishes a regulatory pathway that could unleash a wave of generic competition for a class of drugs previously shielded by immense technical and financial barriers.

A New Precedent in Pharmaceutical Manufacturing

The significance of the FDA's green light cannot be overstated. Oligonucleotides, short strands of synthetic DNA or RNA that can precisely target the genetic roots of disease, are notoriously difficult and expensive to produce at scale. For years, their production has been the exclusive domain of a handful of specialized firms and Big Pharma, keeping prices high and access limited. Aurisco's achievement marks the first time a manufacturer has successfully demonstrated to the stringent USFDA its capability to produce a generic version of these complex molecules while adhering to current Good Manufacturing Practice (cGMP) standards.

The inspection report confirmed that the company had successfully addressed all observations through an approved Corrective and Preventive Action (CAPA) plan, a testament to a mature and responsive quality management system. According to the company's press release, the FDA inspector expressed satisfaction with the facilities, documentation, and the expertise of the team.

"This was the first FDA inspection to a generic oligonucleotide manufacturer," said Dr. Wang Guoping, the site's General Manager. "We are collaborating with agencies worldwide to establish pathways for generic TIDES (peptides and oligonucleotides)." His statement underscores the pioneering nature of this approval. It’s not just a win for one company; it’s about creating a replicable blueprint for others to follow, fundamentally altering the economics of next-generation therapeutics.

Cracking the Code of High-Cost Therapies

The immediate focus of the inspection was Inclisiran, a small interfering RNA (siRNA) therapy marketed by Novartis as Leqvio. The drug works by preventing the liver from producing PCSK9, a protein that hinders the body's ability to clear LDL, or "bad," cholesterol. Administered just twice a year, it offers a powerful alternative for patients who struggle with statins. However, its high price has been a significant barrier to widespread adoption.

The prospect of a generic API for Inclisiran is a game-changer. By driving down the cost of the most critical component, Aurisco's success paves the way for future generic drug products that could be offered at a fraction of the brand-name price. This holds profound implications for public health, particularly in the fight against cardiovascular disease, a leading cause of death globally. Increased affordability would expand access for millions of patients and alleviate budgetary pressures on healthcare systems worldwide.

Furthermore, Aurisco has signaled its ambitions extend beyond a single product. The company explicitly mentioned the potential for future generic versions of other blockbuster oligonucleotides, including Vutrisiran (for transthyretin-mediated amyloidosis), Nusinersen (for spinal muscular atrophy), and Eplontersen (for polyneuropathy). Each of these drugs treats a serious, often debilitating condition, and the introduction of generic competition would bring hope and relief to thousands of families.

The Story Behind the Appointment: China's Ascending Role

From a governance and strategy perspective, Aurisco's milestone is a powerful data point in the narrative of China's evolving role in the global pharmaceutical industry. For decades, Chinese manufacturers were primarily known as suppliers of low-cost, simple chemical APIs. This approval demonstrates a decisive shift towards the highest end of the value chain: complex, high-specification biological products that meet the world's most rigorous regulatory standards.

This is not an overnight success. Founded in 1998, Aurisco has strategically built a global infrastructure that includes four manufacturing sites, six R&D centers, and a team of 300 scientists. With over 100 patents filed, the company has clearly invested for the long term, focusing on building a defensible moat of intellectual property and technical know-how in the complex TIDES sector. Its commitment is further evidenced by its recent establishment of an AI-Driven Oligonucleotide Drugs Discovery Laboratory, signaling a push into the very frontier of pharmaceutical innovation.

Moreover, the company appears to understand the demands of operating as a top-tier global supplier. Its Ecovadis Gold ranking for sustainability and membership in initiatives like the Science Based Targets initiative (SBTi) show a corporation aligning itself with the stringent ESG (Environmental, Social, and Governance) expectations of multinational partners. This holistic approach—combining technical excellence, regulatory compliance, and corporate responsibility—is what transforms a regional manufacturer into a global powerhouse.

Navigating the Regulatory Gauntlet

Achieving this approval was a monumental technical and regulatory feat. The FDA itself has acknowledged the unique challenges in creating generic oligonucleotides, particularly around proving that the generic molecule is identical to the original in structure, purity, and stereochemistry. Aurisco's ability to successfully navigate this complex process provides invaluable data and sets a precedent for future applicants.

Board Director Dr. Li Jinliang celebrated the achievement as marking "the beginning of a new era of safe and affordable oligonucleotides for patients." His words capture the dual promise of this breakthrough: maintaining the highest standards of safety while radically improving affordability.

Of course, the path to a cheaper bottle of medicine on the pharmacy shelf is not yet complete. The API manufacturing approval is a critical first step, but the final generic drug will still need to clear its own regulatory hurdles and, crucially, navigate the complex web of patent protections that surround the brand-name product. With patents on Leqvio extending into the mid-2030s, a market launch is not imminent. However, the most difficult part—proving that a high-quality, generic version can be made—is now a matter of public record. Aurisco has fired the starting gun, and for patients and healthcare providers, the race toward more accessible medicine has officially begun.